Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
7(44%)
Results Posted
50%(1 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_1
3
19%
Ph phase_2
12
75%
Ph phase_3
1
6%

Phase Distribution

3

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
12(75.0%)
Phase 3Large-scale testing
1(6.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

7

trials recruiting

Total Trials

16

all time

Status Distribution
Active(9)
Completed(2)
Terminated(2)
Other(3)

Detailed Status

Active, not recruiting7
unknown3
Completed2
Not yet recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
16
Active
7
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (18.8%)
Phase 212 (75.0%)
Phase 31 (6.3%)

Trials by Status

completed213%
active_not_recruiting744%
not_yet_recruiting213%
unknown319%
terminated213%

Recent Activity

7 active trials
Showing 5 of 16
terminatedphase_1

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT01898793
unknownphase_1

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

NCT05108077
terminatedphase_2

Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer

NCT03002831
active_not_recruitingphase_2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

NCT02482454
unknownphase_1

Study of DC-CTL Combined With CIK for Advanced Solid Tumor

NCT03047525
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT01898793Phase 1

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated
NCT05108077Phase 1

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Unknown
NCT03002831Phase 2

Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer

Terminated
NCT02482454Phase 2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Active Not Recruiting
NCT03047525Phase 1

Study of DC-CTL Combined With CIK for Advanced Solid Tumor

Unknown
NCT01749865Phase 3

CIK Treatment for HCC Patient Underwent Radical Resection

Completed
NCT02487992Phase 2

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

Active Not Recruiting
NCT02490748Phase 2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Active Not Recruiting
NCT02487693Phase 2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Active Not Recruiting
NCT02489890Phase 2

CIK in Treating Patients With Bladder Cancer

Active Not Recruiting
NCT02485015Phase 2

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active Not Recruiting
NCT02493582Phase 2

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Active Not Recruiting
NCT02498756Phase 2

Cytokine-induced Killer Study for Patients With Stage II Melanoma

Not Yet Recruiting
NCT02490735Phase 2

CIK in Treating Patients With Esophageal Cancer

Not Yet Recruiting
NCT02419677Phase 2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Completed
NCT01929499Phase 2

Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Unknown

All 16 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
16